The treatment exhibits ovarioprotective effects, downregulates serum testosterone, and restores insulin resistance (IR). It inhibits inflammatory cell infiltration in ovarian tissues, decreases the expression of IRS1, PI3K, and AKT, and increases the expression of GLUT4 and PTEN. The gene discussed is IRS1; the disease is Insulin resistance.